Which pharmacotherapy is most strongly associated with successful smoking cessation when added to behavioral counseling?

Which pharmacotherapy is most strongly associated with successful smoking cessation when added to behavioral counseling?

• A. Nicotine gum
• B. Bupropion
• C. Nortriptyline
• D. Varenicline

Answer: (D)

Varenicline is the pharmacotherapy most strongly associated with successful smoking cessation when added to behavioral counseling. It works as a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor in the brain, which gives enough receptor stimulation to ease withdrawal while blocking nicotine from cigarettes from delivering its full rewarding effect. This combination reduces craving and makes smoking less reinforcing, which translates into higher quit rates when paired with counseling. Across multiple trials, varenicline consistently shows higher abstinence rates than nicotine replacement therapies and bupropion, both in the short term and over longer follow-ups. This superior effectiveness is why it’s generally favored when a pharmacotherapy is added to counseling. Common side effects include nausea and sleep disturbances, and while there are cautions for people with active psychiatric illness, most patients tolerate it well with proper monitoring. Nicotine gum and other nicotine replacement options help with withdrawal but typically yield lower quit rates than varenicline in head-to-head comparisons. Nortriptyline is an older option with more adverse effects and less robust evidence for smoking cessation. Bupropion is effective but, on average, does not achieve quit rates as high as varenicline.

Varenicline is the pharmacotherapy most strongly associated with successful smoking cessation when added to behavioral counseling. It works as a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor in the brain, which gives enough receptor stimulation to ease withdrawal while blocking nicotine from cigarettes from delivering its full rewarding effect. This combination reduces craving and makes smoking less reinforcing, which translates into higher quit rates when paired with counseling.

Across multiple trials, varenicline consistently shows higher abstinence rates than nicotine replacement therapies and bupropion, both in the short term and over longer follow-ups. This superior effectiveness is why it’s generally favored when a pharmacotherapy is added to counseling. Common side effects include nausea and sleep disturbances, and while there are cautions for people with active psychiatric illness, most patients tolerate it well with proper monitoring.

Nicotine gum and other nicotine replacement options help with withdrawal but typically yield lower quit rates than varenicline in head-to-head comparisons. Nortriptyline is an older option with more adverse effects and less robust evidence for smoking cessation. Bupropion is effective but, on average, does not achieve quit rates as high as varenicline.